- Home
- CNVS vs STTK Comparison
CNVS vs STTK Comparison
Compare CNVS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNVS
- STTK
- Stock Information
- Founded
- CNVS 2000
- STTK 2016
- Country
- CNVS United States
- STTK United States
- Employees
- CNVS N/A
- STTK N/A
- Industry
- CNVS Consumer Electronics/Video Chains
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- CNVS Consumer Discretionary
- STTK Health Care
- Exchange
- CNVS Nasdaq
- STTK Nasdaq
- Market Cap
- CNVS 57.8M
- STTK 54.4M
- IPO Year
- CNVS 2003
- STTK 2020
- Fundamental
- Price
- CNVS $3.51
- STTK $1.16
- Analyst Decision
- CNVS Buy
- STTK Hold
- Analyst Count
- CNVS 1
- STTK 3
- Target Price
- CNVS $10.00
- STTK $2.00
- AVG Volume (30 Days)
- CNVS 251.1K
- STTK 332.9K
- Earning Date
- CNVS 02-12-2025
- STTK 11-14-2024
- Dividend Yield
- CNVS N/A
- STTK N/A
- EPS Growth
- CNVS N/A
- STTK N/A
- EPS
- CNVS N/A
- STTK N/A
- Revenue
- CNVS $45,005,000.00
- STTK $6,435,000.00
- Revenue This Year
- CNVS $50.96
- STTK $313.04
- Revenue Next Year
- CNVS N/A
- STTK N/A
- P/E Ratio
- CNVS N/A
- STTK N/A
- Revenue Growth
- CNVS N/A
- STTK 382.75
- 52 Week Low
- CNVS $0.72
- STTK $0.94
- 52 Week High
- CNVS $4.19
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- CNVS 50.34
- STTK 44.02
- Support Level
- CNVS $3.32
- STTK $1.07
- Resistance Level
- CNVS $4.04
- STTK $1.38
- Average True Range (ATR)
- CNVS 0.28
- STTK 0.12
- MACD
- CNVS -0.10
- STTK 0.01
- Stochastic Oscillator
- CNVS 16.03
- STTK 27.88
About CNVS Cineverse Corp.
Cineverse Corp is a main streaming technology and entertainment company. It operates portfolios of owned and operated streaming channels, all powered by its, proprietary technology platform. Cineverse features enthusiast brands for subscription video on demand (SVOD), advertising-based video on demand (AVOD), and free, ad-supported streaming television (FAST) channels. The company earns fees for the distribution of content in the home entertainment markets via several distribution channels, including digital, video-on-demand, and physical goods (e.g., DVDs and Blu-ray Discs) (Base Distribution).
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.